Daratumumab

• A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) Pending
  2024-513917-11-01 Phase I/II 1 country Uniwersytet Medyczny W Lublinie
• Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure Pending
  2024-514702-31-00 Phase II 1 country Medizinische Universitaet Innsbruck
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
• ETCABio - Evaluation of Skin Tests in Biotherapy Allergies Pending
  2024-519812-15-00 Phase IV 1 country Centre Hospitalier Universitaire D'Angers
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 Phase III 6 countries AstraZeneca AB
• A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending
  2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 Phase II 4 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Comb… Recruiting
  2024-518588-36-00 Phase III 2 countries Celltrion Inc.
• A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting
  2024-511855-16-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-… Recruiting
  2024-515770-27-00 Phase I/II 1 country AbbVie Deutschland GmbH & Co. KG
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum… Recruiting
  2025-520897-21-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
• A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim… Recruiting
  2024-517140-65-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab… Recruiting
  2024-519827-16-00 Phase III 16 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting
  2024-516418-39-00 Phase III 1 country Intergroupe Francophone Du Myelome
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting
  2024-517325-43-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• Plasma cell targeting in ME/CFS Recruiting
  2024-520094-13-00 Phase II 1 country Helse Bergen HF
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b… Recruiting
  2024-519498-20-00 Phase I/II 1 country Cellcentric Limited
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting
  2024-516030-35-00 Phase III 11 countries Glaxosmithkline Research & Development Limited
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting
  2024-515279-37-00 Phase III 17 countries Celgene Corp.
• Reduction of plasma cells as an approach to reset autoimmunity in rheumatoid arthritis Recruiting
  2024-511536-27-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 Phase III 9 countries Kite Pharma Inc.
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting
  2023-507751-30-00 Phase I/II 5 countries BeOne Medicines AG
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom… Recruiting
  2023-507632-20-00 Phase III 9 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–24 of 77 trials